Edgen Stock·Sep 25 2025, 21:05戻る
戻る
Intellia Therapeutics Reports Positive Long-Term Phase 1 Data for Nexiguran Ziclumeran in ATTRv-PN
Edgen Stock·Sep 25 2025, 21:05
[1] Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug[2] Amvuttra's stellar performance pushes Alnylam's guidance, stock higher - FirstWord Pharma[3] Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy